Depression has become one of the most severe psychiatric disorders and endangers the
health of living beings all over the world. In order to explore the molecular mechanism that …

Rationale Prior reviews have examined how stress, broadly defined, interacts with genetic
diathesis in the pathogenesis of internalizing (ie, depressive and anxiety) disorders. Recent …

Animal models and preclinical tests have played large roles in the development of
antidepressant drugs and are likely to continue to play important roles. In the present …

Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as
a neutral antagonist at 5‐HT2C receptors. Accumulating evidence in a broad range of …

Early life stress is one of the best characterized risk factors for psychiatric disorders,
including depression, and many animal models have therefore studied the long-term …

While modern neurobiology methods are necessary they are not sufficient to elucidate
etiology and pathophysiology of affective disorders and develop new treatments …

Since the serendipitous discovery of the first class of modern antidepressants in the 1950's,
all pharmacotherapies approved by the Food and Drug Administration for major depressive …

Rationale Escitalopram is a widely used antidepressant for the treatment of patients with
major depression. It is the pure S-enantiomer of racemic citalopram. Several clinical trials …

Repetitive transcranial magnetic stimulation (rTMS) has been demonstrated in the pre-
clinical and clinical settings to have an antidepressant effect. However, studies on the long …

Polyglutamine diseases are a class of dominantly inherited neurodegenerative disorders for
which there is no effective treatment. Here we provide evidence that activation of …